BRIEF-AstraZeneca's Enhertu Gets U.S. Nod For Treatment Of Advanced Gastric Cancer In Some Patients

Reuters | Updated: 18-01-2021 18:41 IST | Created: 18-01-2021 18:15 IST
BRIEF-AstraZeneca's Enhertu Gets U.S. Nod For Treatment Of Advanced Gastric Cancer In Some Patients
Representative image Image Credit: Twitter (@AstraZeneca)

AstraZeneca PLC:

* ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) APPROVED IN THE US FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE ADVANCED GASTRIC CANCER Source text for Eikon: Further company coverage:

TRENDING

1
ROI-The energy transition is starting to feed itself: Maguire

ROI-The energy transition is starting to feed itself: Maguire

Global
2
Georgia block party shooting kills two, injures dozens

Georgia block party shooting kills two, injures dozens

Global
3
Brazil's Flavio Bolsonaro beats polls in presidential vote, faces Lula in runoff

Brazil's Flavio Bolsonaro beats polls in presidential vote, faces Lula in ru...

Global
4
Paraguay opposition candidate wins Asuncion mayor's race in gauge of 2028 vote

Paraguay opposition candidate wins Asuncion mayor's race in gauge of 2028 vo...

Global

PERSPECTIVES AND INSIGHTS

Beyond Megawatts: Why Clean Energy’s Real Test Is Creating Jobs, Skills and Better Livelihoods

Beyond English-Led AI: How Local Languages Could Unlock New Markets, Jobs and Public Services

From EVs to AI: Why the Future of Global Manufacturing May Depend on Small Businesses

Climate Tariffs Could Reshape Who Wins and Loses Across Global Value Chains

DevShots

Latest News

Connect us on

LinkedIn Quora Youtube RSS
Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.

Subscribe to our Newsletter  

STANDARDS & POLICIES

EDITIONS

OTHER LINKS

CONNECT

Devdiscourse
Disclaimer | Terms of use | Privacy Policy

© Copyright 2026